OpenAI acquires Orchestra Bio, a drug development coordination platform, to build agents with its Rosalind life sciences tools
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team!
Context
OpenAI is moving from helping scientists with research into running the operational side of bringing new medicines to patients.
Rosalind is OpenAI's set of AI models and tools for life sciences, including GPT Rosalind and Rosalind Workbench. OpenAI did not disclose the price of the acquisition.
Deep dive
On October 20, OpenAI posted that it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development, and that together they will build on Rosalind to streamline those operations and help new treatments reach patients sooner. It welcomed the company's founder, @ashokaraj_, and team.
OpenAI's announcement says developing a new medicine takes roughly 10 to 15 years on average in the United States, and that beyond the science, teams must coordinate programs across departments and outside partners, often with disconnected systems.
According to OpenAI, Orchestra is a platform where people and AI agents work together on drug programs, with agents monitoring and tracking studies. It gives the example of a failed manufacturing batch that delays a clinical trial: Orchestra's agents identify which activities and timelines are affected, gather the relevant information and compare responses, and people decide what to do.
OpenAI said it aims to build agents that connect scientific findings with the studies, decisions and next steps needed to advance a medicine. It pointed to its partnerships with Novo Nordisk and Moderna as examples of working with drug companies.
OpenAI did not disclose deal terms or say whether Orchestra's product will stay available to its current customers. The announcement came on the same day Anthropic published its own life sciences result, Claude's work on scorpion toxin binders.
What to expect next
Watch for OpenAI to say whether Orchestra's platform stays available as a product or is folded into Rosalind, and what happens to current customers. Also watch for drug companies to announce use of the combined tools, beyond the Novo Nordisk and Moderna partnerships OpenAI named. Competition with Anthropic and Google in life sciences is heating up, so more acquisitions in the field would not be a surprise.